Interim data suggests reduced risk of progression or death in the CM24/nivolumab plus standard of care Nal-IRI/5FU/LV arm of the study The interim data in the CM24/nivolumab plus SoC Nal-IRI/5FU/LV ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results